I wonder if any gamblers noticed my post 334 on the GMC thread yesterday.
It looks as though bottom fishing can sometimes pay off.

Can you give any reason(s) why Guinness69?

Looks like time for bottom fishers to celebrate again, but no idea why ELA is climbing.
They have crawled upwards throughout the year, then suddenly spurted recently. The chairman spent 1/3M on shares at the beginning of November and in the last couple of days US brokers have upgraded their rating. There is just a possibility that their flagship drug, Tsybari, is about to be re-approved and if so the sp will go through the ceiling, but I can't find anything - can anybody?
sd.

Wall St AFX News reports that ELA was Tuesday's most heavily traded European stock, even ahead of Vodaphone, on expectations that Tsybari would shortly return to the market. Meanwhile, there's profit taking here today.

Thanks for the nudge on this one earlier in the year squidd, a very nice gain so far.

Good news this morning. The U.S. FDA has recognised the significance of the flagship drug Tsybari and granted it 'priority review status'. Hence the sp jump.
sd.

ELA continuing its upward crawl and has even put on a spurt recently. Now again at a post crash high and everyone should have at least doubled their money. Still more to come I think.
sd.

Another mini leap this morning, over 5% up on opening.
sd.

There was a huge share purchase by the chairman at the beginning of November and now over the past 3 days we are seeing a dramatic rise. I wonder if news is leaking out about re-approval of their flagship drug Tsybari.
sd.

I like the look of this one squidd the end of period cash balances are going up! and losses going down! hope it's not too late to add to my ISA for a profit sorry I missed your posts on it now! I'm holding MDY and hoping as driver has high hopes it will pay off.

I like the look of this too.Never noticed it before looking at this thread and it will be going on my watch list.Do you think its looking overbought at the moment.

Soundings among my medic contacts suggest that there is virtually no other treatment for multiple sclerosis, so if Tsybari were re-approved in could be huge.
Meanwhile, the FDA and the manufacturers keep making optimistic noises.
I've been adding to ELA from sales of AEX, which seems to have temporarily run out of steam
sd.

This looks one of the biggest punts around, based mainly on one single win or bust treatment, but the chart says 20p pdq. Considering a gamble.
Any chance of some charts in the header, thanks for flagging it up squidd, even if i am a tad late in noticing the potential!

hawick: This chart gives the latest picture, though I usually work on a series of Sharescope charts which I find gives a more comprehensive picture, and suggested to me back in March that this was a classic recovery scenario.

moneyplus: Looking at the above mentioned charts for MDY, it looks to me as if it's still in downtrend and hasn't bottomed yet. Worth keeping on the watch list though.
sd.

ELA seems to be gathering momentum, now up 60% since 1st Nov and 25% this month. It has overtaken everything else in my portfolio, even PMK, as my Winter front runner. I think the chairman must have known something about re-approval of Tsybari when he made that hefty share purchase 3 months ago.
Hope there are many of on board.
sd.

And up another 7% on opening this morning; wish I could dig up some news.
sd.

Thanks Squidd, my chart analysis still says 20, after a very brief pause on the way up around 15. Timing is hard but the chart has certain similarities to PMK (I said 25p on it when it was 10p and did nothing about it!), Good luck.

hawick: I agree with you on the chart forecast, but look also at the 10year chart, could ELA return to the glory days of 40? They have streamlined their operations and have a good pipeline of new drugs led by Tsybari; and the pharma industry as a whole must be encouraged by the failure so far of the Vioxx litigants to screw Merck. Even higher risk now it's so far off the bottom, but I'm still buying.
Horrified to hear you didn't get into PMK.

In recent weeks, 2 other drugs that treat MS, one based on on cannabis and the other on goats milk, have had to be withdrawn owing to side effects. Increasingly, Tsybari is emerging as the only treatment for MS and various other illnesses and should it be re-approved, it will undoubtedly be a blockbuster so propelling ELA to new heights.
Meanwhile, a year end spurt in the sp made ELA my top performer of 2005, beating the likes of ULT, AEX and CSB. More to come in 2006 I'm thinking.
Prosperous New Year to all,
sd.

ELA continues its steep climb and is still leading the pack.

Well and truly filling the gap to E20.